Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
27 Novembro 2024 - 10:39AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
November, 2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date:
November 27, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
November 27, 2024
National Stock Exchange of India Ltd. (Scrip
Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code:
RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
| Ref: | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 |
This is to inform that the Company has received
fine notices from Federal Administration Office, Bad Homburg, Germany for our wholly owned subsidiary companies in Germany – betapharm
Arzneimittel GmbH and Reddy Holding GmbH. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 are as hereunder:
A) |
Name of the authority |
: |
Federal Administration Office, Homburg, Germany |
B) |
Nature and details of the action(s) taken, initiated or order(s) passed |
: |
The Company received the fine notices from Federal Administration
Office, Bad Homburg, Germany for breach of legal obligation to register the “beneficial owners” in the German Transparency
Register for following two wholly owned subsidiary companies incorporated in Germany. The details of fine imposed is as follows:
· betapharm Arzneimittel GmbH - € 8,584.63
· Reddy
Holding GmbH - €10,569.13
|
C) |
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
: |
Date of receipt of orders: October 22, 2024. |
D) |
Details of the violation(s)/ contravention(s) committed or alleged to be committed |
: |
Breach of legal obligation to register the “beneficial owners”
in the German Transparency Register within the prescribed timeline.
Further, the Company has taken the corrective
action and registered the beneficial ownership of the said subsidiaries in German Transparency Register. |
E) |
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
: |
As stated in point (B) above. Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company |
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer &
Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Dr Reddys Laboratories (NYSE:RDY)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024